Abobotulinumtoxin A

(Dysport®)

Dysport®

Drug updated on 5/17/2024

Dosage FormInjection (intramuscular; 300 units, 500 units)
Drug ClassMultiple
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of cervical dystonia in adults.
  • Indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults < 65 years of age.
  • Indicated for the treatment of spasticity in patients 2 years of age and older.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Abobotulinumtoxin A (Dysport) is approved for the use in the management of cervical dystonia in adults, the temporary enhancement of moderate to severe glabellar lines due to procerus and corrugator muscle activity in adults under 65 years of age, and for managing spasticity in patients aged 2 years and older.
  • Seven systematic reviews/meta-analyses were analyzed, covering a variety of applications from therapeutic treatments such as cervical dystonia and spasticity, to cosmetic improvements like the reduction of facial lines.
  • Dysport demonstrated potentially superior outcomes compared to OnabotulinumtoxinA in reducing episodes of urinary incontinence, particularly at doses of 800U. There were similar rates of treatment-emergent urinary tract infections, indicating comparable safety profiles.
  • For cosmetic applications, favorable results across multiple off-label uses were observed, indicating effectiveness with high patient satisfaction. There were no serious adverse events, suggesting a beneficial safety profile.
  • In the management of hyperhidrosis or excessive sweating, Dysport showed positive outcomes for various types, including axillary and palmar, with high patient satisfaction. The absence of reported serious adverse events highlights its strong safety profile for this condition.
  • In pediatric patients experiencing lower limb spasticity, significant benefits over OnabotulinumtoxinA in terms of tone and functional outcomes were noted, while maintaining similar tolerability. This emphasizes its potential value in pediatric care strategies.

Product Monograph / Prescribing Information

Document TitleYearSource
Dysport (abobotulinumtoxin A) Prescribing Information.2020Ipsen Biopharmaceuticals, Inc., Cambridge, Fort Worth, TX

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Oscar clinical guideline: botulinum toxin.2017OSCAR